<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01117376</url>
  </required_header>
  <id_info>
    <org_study_id>CT-88-01-36-1601</org_study_id>
    <nct_id>NCT01117376</nct_id>
  </id_info>
  <brief_title>Methylnaltrexone vs Erythromycin for Facilitating Gastric Emptying Time in Critically Ill Patients</brief_title>
  <official_title>Methylnaltrexone vs Erythromycin for Facilitating Gastric Emptying Time in Critically Ill Patients Intolerant to Enteral Feeding</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shiraz University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shiraz University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      42 patients admitted in ICU with intolerance to enteral feeding (GRV more than 250 ml) are
      recruited. All patients enter a primary acetaminophen absorption test study as baseline.
      Serum levels of acetaminophen will be measured by florescence polarization method at
      15,30,45,60,90,120,180,240,480 minutes after enteral administration of 975 mg acetaminophen.
      Then the patients will be randomized to methylnaltrexone or erythromycin group.Another
      acetaminophen absorption test with the same schedule will be done after the last dose of each
      drug.The area under the curve for acetaminophen blood level will be used to compare the
      effect of two studied drugs on gastric emptying time.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was prematurely terminated because of unavailibility of Methylnaltrexone in the
    region
  </why_stopped>
  <start_date>May 2010</start_date>
  <completion_date type="Anticipated">August 2011</completion_date>
  <primary_completion_date type="Anticipated">June 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gastric emptying time</measure>
    <time_frame>within 8 hours after drug administration</time_frame>
    <description>to measure gastric emptying time within 8 hours after administration of either 4 doses of 250 mg intravenous erythromycin Q6h or 2 doses of methylnaltrexone 12 mg subcutaneous Q12h with acetaminophen absorption test method</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerance to enteral feeding</measure>
    <time_frame>24 hours after intervention</time_frame>
    <description>Tolerance to enteral feeding administered via nasogastric tube within 24 hours after administration of either erithromycin 250 mg intravenous Q6h or methylnaltrexone 12 mg subcutaneous Q12h.Gastric residual volume will be measured Q4h by aspiration method and if less than 250 ml would be considered as tolerance to enteral feeding.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Gastroparesis</condition>
  <arm_group>
    <arm_group_label>Erythromycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>21 patients admitted in ICU with intolerance to enteral feeding defined as more than 250 ml of gastric residual volume (GRV) found by aspiration technique.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methylnaltrexone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>21 patients admitted in ICU with intolerance to enteral feeding defined as more than 250 ml of gastric residual volume (GRV) found by aspiration technique.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erythromycin</intervention_name>
    <description>Erythromycin 250 mg intravenous Q6h for 4 doses</description>
    <arm_group_label>Erythromycin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylnaltrexone</intervention_name>
    <description>Methylnaltrexone 12 mg subcutaneous Q12h for 2 doses</description>
    <arm_group_label>Methylnaltrexone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients admitted in intensive care unit in a university affiliated hospital

          -  Receiving continuous enteral feeding through a nasogastric tube

          -  Gastric residual volume more than 250 ml checked by aspiration technique

        Exclusion Criteria:

          -  Receiving the study drugs or metoclopramide within 24 hours of inclusion

          -  Known allergy to interventional drugs or acetaminophen

          -  Gastrointestinal bleeding or surgery on GI system within 24 hours of inclusion

          -  Crohn's disease

          -  GI perforation or obstruction

          -  Short bowel syndrome

          -  Liver failure or 2 of the followings:

               -  Transaminase enzymes more than 3 times normal

               -  Prothrombin time more than 2 times normal

               -  Total bilirubin more than 3 times normal

          -  Patients on hemodialysis or CRRT

          -  Hemodynamically unstable patients including:

               -  Mean arterial pressure less than 65 mmHg

               -  Infusion of inotropes and vasopressors

               -  Uncorrected acute blood loss; hemoglobin concentration less than 6.5 mg%.

          -  Documented or suspected pregnancy

          -  Obesity; actual body weight more than 1.5 times ideal body weight

          -  Myasthenia Gravis.

          -  Opioid drug abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nemazee Hospital</name>
      <address>
        <city>Shiraz</city>
        <state>Fars</state>
        <zip>71937-11351</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 30, 2010</study_first_submitted>
  <study_first_submitted_qc>May 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2010</study_first_posted>
  <last_update_submitted>March 30, 2011</last_update_submitted>
  <last_update_submitted_qc>March 30, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 31, 2011</last_update_posted>
  <responsible_party>
    <name_title>M. H. Dabbaghmanesh</name_title>
    <organization>Shiraz University of Medical Sciences</organization>
  </responsible_party>
  <keyword>Gastroparesis</keyword>
  <keyword>Erythromycin</keyword>
  <keyword>Methylnaltrexone</keyword>
  <keyword>ICU</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
    <mesh_term>Gastroparesis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erythromycin</mesh_term>
    <mesh_term>Erythromycin Estolate</mesh_term>
    <mesh_term>Erythromycin Ethylsuccinate</mesh_term>
    <mesh_term>Erythromycin stearate</mesh_term>
    <mesh_term>Methylnaltrexone</mesh_term>
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

